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ABSTRACT

Cancer cells can be viewed as such cells, which have disrupted/aberrant
signaling pathways for maintaining cellular homoeostasis. Identifying such
altered signaling mechanisms can help us target these pathways in a better way.
GDF-2 (Growth and differentiation factor – 2) or BMP9 (Bone morphogenetic
protein – 9), a multifunctional cytokine, is a member of the Bone Morphogenetic
Protein subfamily, under TGFβ superfamily, with roles distinct from BMP2/4/7.
While GDF-2 is known to be one of the most potent ectopic inducers of bone and
cartilage formation, it rose to significance with the identification of its receptor
ALK1 in endothelial cells. TGFβ’s role in cancer progression could be described
as both agonistic and antagonistic. It maintains tissue homeostasis and prevents
incipient tumors from progressing down the path to malignancy. But cancer cells
have the capacity to avoid the suppressive influence of TGFβ pathway.
Pathological forms of TGFβ signaling promote tumor growth and invasion,
evasion of immune surveillance and cancer cell metastasis. Apart from the Cterminal phosphorylation of smad2/3 by TGFβ, it can also phosphorylate the
linker region. We find that GDF-2 can regulate smad phosphorylation by
phosphorylating smad1/5 at the C-terminus to regulate cell survival [1-5].
Interestingly, GDF2 can also mediate linker phosphorylation of smad2 and not
smad1 in a subset of epithelial cancer and non-cancerous cells. My Studies
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indicate that GDF-2 mediated linker smad2 phosphorylation can antagonize
TGFβ signaling implicating that the balance in the level of growth factors is an
important

factor

in

mediating

downstream

v

signaling

pathways.
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CHAPTER 1

INTRODUCTION
1.1 IMPORTANCE OF GDF-2
TGFβ superfamily members have various roles in tumorigenesis. They
promote cancer in its advanced stage as well as inhibit it in its early stages [6].
BMPs comprise an extensive group of conserved and related growth factors, of
which approximately 20 have been identified so far. BMPs were first identified in
the extract of bones and were known for their ability to be involved in direct
ectopic bone formation [7]. Subsequently, apart from being involved in bone
formation, BMPs were found to be involved in many developmental processes
like embryonic patterning and early skeletal formation. BMPs also regulate tooth,
hair, kidney, muscle, skin, and hematopoietic and neuronal development and
also maintain the iron metabolism and vascular homeostasis in vivo [7]. BMPs
are divided into 4 subgroups according to the similarity of their amino acid
sequences and functions. The BMP-2/4 subgroup includes BMP-2, BMP-4 and
the Drosophila dpp, functioning in the embryonic development. The BMP-7
subgroup is composed of BMP-5, 6, 7, 8 and the Drosophil gbb. The third is
GDF-5 subgroup, including GDF-5, 6 and 7. These three subgroups are
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important for keeping up normal tissue functions. BMP 9 and BMP 10 are the
member of a fourth subgroup whose functions are now being discovered [8].
BMPs act through two different type II and type I serine/threonine kinase
receptors, which are required for downstream signal transduction. The
serine/threonine kinase domains of type II receptors are constitutively active, and
phosphorylate Gly-Ser (GS) domains in the type I receptors upon ligand binding,
leading to the activation of type I receptor kinases. BMPs bind to three different
type II receptors, i.e. BMP type II receptor (BMPR II), activin type II receptor
(ActR II) and activin type IIB receptors (ActR IIB). Regarding type I receptors,
BMPs bind to three different type I receptors, called activin receptor like kinase
(ALK) 2, ALK3 and ALK6 [9].
1.2 OVERVIEW OF THE SIGNALING PATHWAY
The gdf-2 gene encodes BMP-9, also known as GDF-2. The role of GDF-2
in vascularization and angiogenesis has revealed roles in suppressing
angiogenesis and promoting proliferation in endothelial cells [1, 2, 10, 11]. There
is little information on the effects of GDF-2 in epithelial cells. The significance of
GDF-2’s role in epithelial cells comes from the facts that it is predominantly
expressed in liver, although it’s expression has also been detected in skin and
heart as well. It also acts as a differentiation factor in the central nervous system
[12] and it promotes proliferation of hepatocytes [3, 4, 13]. GDF-2 is also shown
to be a suppressor of breast cancer in vivo [5]. GDF-2 signaling in endothelial
cells is initiated when it binds to the heteromeric type I/type II receptors. Two
distinct type I receptor serine threonine kinases have been shown to bind GDF-2:
2

ALK1 in endothelial cells [1, 14] and ALK2 in other cell types [1, 4, 15] and also
ALK3 and ALK6, in the absence of ALK1 and low ALK2. There are three distinct
type II receptors, which bind to GDF-2: BMPR II, ActRII and ActRII B [1, 15]. But
the binding of GDF-2 to type I and type II receptors varies in different cell types.
Once the ligand binds the receptors, they are activated which in turn activates
the receptor regulated smads (R-SMADs) smad1, smad5 and smad8, which in
turn forms a complex with the co-smad smad4. This whole complex gets trans
located into the nucleus and along with other transcription factors, promotes
target gene expression and regulation [16].

Figure 1.1 Overview of the BMP signaling pathway; Int. J. Mol.
Sci. 2014, 15(11), 20656-20667
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1.3 STRUCTURAL AND FUNCTIONAL PROPERTIES OF GDF-2
Like all other TGFβ ligands, GDF-2 is synthesized as a large pre-proprotein. Once dimerization occurs, the pro domain is cleaved from the active
GDF-2; however, it still remains attached to GDF-2 through non-covalent
interactions [14]. Expression of GDF-2 in different organs has been studied and it
has been found that hepatocytes are by far the best producers of GDF-2 and
moreover, it has been observed that similarly to TGFβ, GDF-2 circulates in active
and inactive forms [17]. However, unlike TGFβ, the pro-domain of GDF-2 does
not bind to ECM, meaning that GDF-2 is not inhibited to enter the circulation,
resulting in a much higher concentration of GDF-2 in the serum [17]. The
estimated level of GDF-2 in the blood is around 2-20 ng/ml, which is much higher
than the EC50 for ALK1 activation. Indeed, aortic endothelial cells showed
endogenously phosphorylated smad1/5/8 proteins, presumably due to sustained
activation by circulating GDF-2 molecules [17].
The functional properties of GDF-2 are not very well understood. In fact,
GDF-2 knockout mice did not show defects in angiogenesis [18], even though
multiple studies have identified GDF-2 as an important factor for vasculature
maintenance [1]. Knockout of the GDF-2 receptor, ALK1, is embryonically lethal,
while haploinsufficiency in ALK1 leads to a genetic disorder called hereditary
hemorrhagic telangiectasia type 2 (HHT2), which is characterized by abnormal
vessel formation [19].
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Early studies have described GDF-2 as a vascular quiescence factor [20].
Subsequent studies have shown that GDF-2 inhibits VEGF-induced
angiogenesis and endothelial cell proliferation [1]. Recent studies, however, have
reported the ability of GDF-2 to mediate proliferation of multiple types of
endothelial cells both in vitro and in vivo, most likely by up regulating VEGF
receptors and Angiopoetin-1/Tie2 expression [2]. These findings are not
surprising, as ALK1 signaling up regulates ID1 and ID3 protein expression [21],
which are strong promoters of angiogenesis [22]. Interestingly, the soluble form
of ALK1 was recently reported to inhibit tumor growth in mouse models [23]. As
with other TGFβ superfamily ligands, the functional role of GDF-2 remains
controversial and is likely extremely cell and context dependent.
Apart from angiogenesis, GDF-2 is also known to have many other effects
in vitro and in vivo. As most other BMPs, GDF-2 can function as an osteogenic
and chondrogenic factor [24]. Additionally, GDF-2 can also regulate metabolism,
by inhibiting glucose production and up regulating important enzymes of lipid
homeostasis [25].
The most intriguing part of GDF-2 signaling is the contradiction of
outcomes in its studies. In breast cancer cells, administering GDF-2 has shown
to decrease HER-2 protein and transcript levels and reduce the tumor volume in
nude mice [26]. On the other hand, GDF-2 acts as a pro-proliferating factor
through the ALK2/SMAD1/SMAD4 pathway in epithelial ovarian cancer cells [15].
This pro-tumorigenic or anti-tumorigenic role of GDF-2 is still a subject of

5

investigation and the gap, whether GDF-2 is a critical factor in cancer
progression remains unexplored
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CHAPTER 2

COMPONENTS OF THE SIGNALING PATHWAY
2.1 SMAD FAMILY

Figure 2.1 The smad family of proteins; Indian Journal of Cancer, Vol. 48, No.
3, July-September, 2011, pp. 351-360
Smads are intracellular proteins, which relay signaling from TGFβ ligands
to the nucleus. There are three types of smads: R-smad (receptor regulated), Cosmad (common mediator) and I-smad (inhibitory). Smads 1, 2, 3, 5, 8 are Rsmads and can be phosphorylated by type I receptors in the C- terminus. Binding
of smad proteins to the type I receptors is aided by the presence of smad anchor
for receptor activation (SARA) protein. Once phosphorylated, smads dissociate
7

from the receptors and form heteromeric complexes with smad4 [27]. Upon
phosphorylation, smad complexes translocate to the nucleus, where they are
able to interact with transcription factors and be recruited to specific promoter
elements. Usually, each type I receptor is associated with only a subset of
smads. Out of ALK 4, 5, 7, all phosphorylate smad2 and smad3, while ALK 1, 2,
3 and 6 induce smad 1, 5, 8 phosphorylation [28].
2.2 NON-SMAD PATHWAYS
2.2.1 P38 PATHWAY
The TGFβ and BMP receptor family not only induces activation of smad
proteins, but also are also capable of activating other signaling molecules such
as MAPKs, ERK, p38 and others. Perhaps the most recognized non-SMAD
pathway initiated by TGFβ superfamily is p38 MAPK pathway. p38 exists at the
third level of MEK phosphorylation, meaning that there are at least two sequential
phosphorylation events before p38 can become phosphorylated. It is thought that
p38 MAPK is activated through MKK3/6 [29]. Further upstream, MKK3/6 is
activated through a TGFβ kinase (TAK1). Multiple studies have shown that TAK1
deficient cells are unable to signal through p38 pathway [30, 31]. Interestingly,
p38 pathway is completely independent from smad signaling, as smad2/3 or
smad4 deficient cells are prefectly capable of activating these pathways [32].
Recent studies have revealed that TGFβ receptors cannot only be
phosphorylated on their serine/threonine residues, but can also be activated
through phosphorylation of tyrosine residues [33]. TβRII cytoplasmic domain
contains three tyrosine residues, which upon phosphorylation can recruit scaffold
8

proteins, which in turn initiate non-SMAD signaling pathways [34].

Figure 2.2 Overview of the MAPK pathway; Can J Ophthalmol. 2009 Aug;
44(4): 431-6

2.2.2 ERK PATHWAY
Several studies have shown that TGFβ can induce ERK activation.
Interestingly, in some cells ERK phosphorylation occurs rapidly within minutes of
TGFβ binding, suggesting a direct method of recruitment [35]. In contrast, other
cells show a delayed response, happening hours after stimulation, implying that
protein synthesis is required for signaling to occur [36]. As in the case of p38
signaling, phosphorylation of tyrosine residues on TβRII plays a crucial role in
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ERK signaling. Moreover, like p38, smad involvement is not needed to induce
ERK phosphorylation [37].
2.2.3 GDF-2 SIGNALING
GDF-2 can also activate non-smad pathways [38]; however, no extensive
research has been done to elucidate the exact mechanisms of smadindependent pathways. It is likely that GDF-2 initiates non-smad signaling
similarly to TGFβ, by phosphorylating tyrosine residues allowing for protein
docking [38]. Several studies have shown that BMPs, including GDF-2 can
induce MAPK pathways, through TAK1, leading to p38 MAPK or JNK activation
[39]. Additionally, BMPs are also shown to induce ERK phosphorylation [39].
Interestingly, GDF-2 has also been found to have an inhibiting effect on PI3K/Akt
pathway, which is activated by TGFβ signaling, implying that ALK1 and ALK5
pathways could function in opposition to each other [40].
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CHAPTER 3

EXPLORING THE LINKER REGION OF SMADS
The R-smads consist of two conserved globular domains, namely the MH1
and MH2 domains connected by a more divergent linker region [41].
The MH1 domain binds DNA, whereas the MH2 domain binds the
membrane receptors for activation, nucleoporins for nuclear translocation, and
other smads and nuclear factors to form transcriptional complexes [42]. The
diversity of the linker region, which consists of several serine and threonine
residues, allows for regulation of R-smads by multiple signaling inputs. The linker
region of smad1 consists of four MAPK phosphorylation sites (Ser-187, 195, 206
and 214), whereas smad2/3 consists of four SP/TP sites for proline-directed
kinases. In response to mitogens, Erk MAPK mediates the phosphorylation of
these sites in vivo [43, 44]. CDK2 and CDK4 have also been known to mediate
the phosphorylation of some of the linker residues in smad2/3 in addition to
residues at the N-terminus of smad2/3 [45]. p38 MAPK and JNK also
phosphorylate the linker region of smad2/3 and regulate their transcriptional
activity [46, 47]. The MAPK mediated phosphorylation of the linker region
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generally results in the inhibition of smad1 activity [43, 48] and attenuation of
nuclear accumulation of smad1 [43]. Similarly, MAPK mediated attenuation of
smad2 activity has been attributed to smad2 linker phosphorylation [44, 49]. In
Xenopus embryogenesis, linker phosphorylation of smad1 through MAPK plays
an important role in inhibiting BMP signaling, which results in neural induction
[48]. Linker phosphorylation of smad2/3 during Xenopus embryogenesis results
in cytosolic retention of smad2/3 and inhibition of TGFβ signaling [49].

Figure 3.1 Different phosphorylation sites of the linker region of smad
proteins; Cell Research (2009) 19:8–20
The TGFβ and BMP pathways are intensely regulated by inputs that
adjust pathway activity according to contextual status. Antagonists such as
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fibroblast growth factor (FGF) and epidermal growth factor (EGF) and cell stress
signals act through MAPKs to cause phosphorylation of a region that links the
DNA binding and transcriptional domains of the smads [43, 48-50]. Linker
phosphorylation of smads in the basal state leads to their cytoplasmic retention
and ubiquitin ligase-driven; proteasomal degradation [51, 52], with an attendant
decrease in the responsiveness of cells to BMP and TGFβ signals [43, 44, 48,
49]. Smad linker phosphorylation by antagonists provides a critical
counterbalance to TGFβ and BMP signaling. This has led to postulates that in the
canonical pathways C-tail phosphorylation activates smad signaling and linker
phosphorylation inhibits it [52, 53]. However, this dichotomy is not so tidy. BMP
induced smad1 linker phosphorylation that has been reported previously [52],
has revealed unexpected facets of the canonical TGFβ and BMP pathways.
Unlike linker phosphorylation by antagonistic signals, which is cytoplasmic and
MAPK mediated, agonist induced linker phosphorylation occurs during or directly
prior to the assembly of smad proteins into transcriptional complexes and is
mediated by CDK8 and CDK9 [54].
MAPK mediated linker phosphorylation appears to have a dual role in
smad2/3 regulation. Mitogens and hyperactive Ras result in extracellular signal
regulated kinase (ERK)-mediated phosphorylation of smad3 at Ser 204, 208 and
Thr 179 and of smad2 at Ser 245/250/255 and Thr 220. Mutation of these sites
increases the ability of smad3 to activate target genes, suggesting that MAPK
phosphorylation of smad3 is inhibitory [44, 55]. However, in contrast, ERK
dependent phosphorylation of smad2 at Thr 8 enhances its transcriptional activity
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[56]. Phosphorylation of smad3 by p38 MAPK and ROCK (Ser 204, Ser 208 and
Ser 213) and c-Jun N-terminal kinase (JNK) (Ser 208 and Ser 213; analogous to
Ser 250 and Ser 255 in smad2) may enhance smad2/3 transcriptional activity,
suggesting that smads and the p38/ROCK/JNK signaling pathways might
cooperate in generating a more robust TGFβ response [46, 47, 57]. A significant
increase in Ser 208/Ser 213 phosphorylation of smad3 is associated with late
stage colorectal tumors, suggesting that the linker-phosphorylated smad3 may
mediate the tumor-promoting role of TGFβ in late tumorigenesis.
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CHAPTER 4

THESIS OBJECTIVES
4.1 RATIONALE
There are many studies where it has been shown that GDF-2 acts through
ALK1 in endothelial cells [1, 10, 58]. GDF-2 can also act via ALK2 [15] in other
cell lines, where ALK1 is absent or present in very low levels. A recent study from
our lab has shown that GDF-2 can also activate smad1/5 signaling by increasing
a complex formation between ALK3 and 6 and type II receptor BMPRII
(unpublished data). As these receptors all induce the smad1/5/8 pathway, it
would suggest that smad independent signaling pathways are also involved.
BMPs are also known to regulate a variety of smad independent pathways
including the p38 and ERK MAPK signaling pathways [9]. Our data suggests that
GDF-2 is also able to induce smad2 but not smad1 linker phosphorylation, which
in turn retain smad2 in the cytoplasm and not allow it to go into the nucleus,
which would further suggest that non smad pathway(s) (p38, ERK) might be
involved upstream of smad2, since canonical smad pathways usually denote C-
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terminal phosphorylation of smads and that leads to nuclear translocation of
smads.
4.2 HYPOTHESIS
GDF-2 phosphorylates the linker region of smad2 and blocks its nuclear
translocation and it also suppresses TGFβ mediated smad2 signaling.
4.3 SPECIFIC AIMS

•

To test whether GDF-2 mediates canonical smad1/5/8 signaling in
tumorigenic ovarian epithelial cells

•

To test whether GDF-2 is able to phosphorylate the linker region of smad2
and prevent its nuclear translocation and whether GDF-2 is able to
suppress TGFβ mediated smad2 signaling.
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CHAPTER 5

MATERIALS AND METHODS
5.1 CELL LINES AND THEIR CULTURE
Ovarian tumorigenic cell lines HEY, 4T1, BT 474, SKOV3 and OvCa 429
were cultured in RPMI supplemented with 10% FBS, L-glutamine and 100U
penicillin/streptomycin. HMvEC cells were maintained in endothelial cell growth
medium containing 10% FBS and MCF10A cells were maintained in DMEM/F12
medium supplemented with 5% horse serum, 20ng/ml EGF, 0.5mg/ml
hydrocortisone, 100ng/ml cholera toxin, 10µg/ml insulin and 100U Pen/Strep. All
cells lines were maintained at 37°C in a humidified incubator at 5% CO2.
5.2 ANTIBODIES, REAGENTS AND PLASMIDS
Antibodies phosphosmad1/5 (#9516S), phosphosmad2/3 (#8828S),
phosphosmad2 (#3104S), smad1 (#6944S), smad2 (#3103S) and p38 MAPK
(#8690S), GAPDH (#2118S) and fibrillarin (#2639S) were from Cell Signaling
Technology. Inhibitors SB203580 (#PHZ1253) and U0126 (#PHZ1283) were
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from Invitrogen. GDF-2 and TGFβ were from R&D systems. Constructs
expressing pE2.1 was a kind gift from Miyazono, K [59].
5.3 TRANSCRIPTION REPORTER LUCIFERASE ASSAY
Cells were grown in a 24 well plate and transfected with pE 2.1 vector
containing the luciferase gene under 36 bp-pE2.1 element of PAI-1 gene [60-62]
and the pRL-SV40 vector expressing Renilla luciferase under the control of SV40
promoter to control for transfection efficiency using Lipofectamine 2000. The cell
were incubated with GDF-2 (10 ng/ml) and TGFβ (100 pM) for 24 hours, after 6
hours of serum starvation in SKOV3 and 24 hours of serum starvation in HEY.
Cells were collected and lysed in 1x passive lysis buffer (Promega) according to
manufacturer’s instructions. To measure luciferase activity, 20µl of lysate was
added to 25µl of Luciferase Reporter Assay Reagent (Promega) and
luminescence was quantitated using a luminometer (Biotek).
5.4 SUB-CELLULAR FRACTIONATION
HEY cells were serum starved (overnight) and treated with the ligands for
30 minutes when they were 90-100% confluent. Then they were harvested from
90-100% confluent P10 dish and subjected to sub-cellular fractionation,
according to the manufacturer’s protocol from the Cell Signaling (#9038S).
5.5 WESTERN BLOTTING
Protein samples were heated to 90°C for 5 minutes and subjected to
sodium dodecyl sulfate-polyacrylamide gel electrophoresis on 10 or 12.5%

18

acrylamide gels, followed by transfer to nitrocellulose membranes for 1 hour at
10 volts. Membranes were blocked for 30 minutes in 5% non-fat dried milk in
Tris-buffered saline, after which they were incubated overnight with primary
antibody in 5% bovine serum albumin in Tris-buffered saline with 0.1% Tween
20, followed by 1 hour with fluorescent secondary antibody.
5.6 IMMUNOFLUORESCENCE AND MICROSCOPY
Cells were fixed in 4% paraformaldehyde, permeabilized in 0.3% TX-100
and blocked with 1% BSA in PBS. Primary antibody (1:200) incubation for an
hour was followed by 30 minutes incubation with Alexa Fluor® 488 (H+L)
(#A11008 Life Technologies). After washing, cells were stained with 4, 6diamidino-2-phenylindole (DAPI; Roche). Imaging was carried out using a Zeiss
LSM700 confocal microscope.

5.7 STATISTICAL ANALYSIS
Statistical analysis was performed by Student’s t-test analysis.
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CHAPTER 6

RESULTS
6.1 GDF-2 activates smad1/5 signaling in both normal and tumorigenic
epithelial cells
It has been known that GDF-2 is a ligand for ALK1 in endothelial cells [10],
but its role in normal and oncogenic epithelial cells that don’t have ALK1 receptor
is still not clear. To find out whether GDF-2 would also mediate downstream
signaling pathways in non-tumorigenic and tumorigenic epithelial cell lines, a time
dependent analysis of smad1/5 phosphorylation was carried out in both
tumorigenic (BT 474, OvCa 429, HEY and SKOV3) and non-tumorigenic
(HMvEC and MCF10A) cell lines. Robust smad1/5 signaling was seen as early
as 5 minutes or 15 minutes after GDF-2 treatment [Figure 6.1]
Since previous studies have indicated that BMP superfamily members
(BMP 2/4) can activate the smad2/3 pathways as well [63], I examined smad2/3
signaling in two of these cell lines. I found out that GDF-2 did not phosphorylate
smad2/3 and subsequently did not mediate smad2/3 signaling [Figure 6.2].
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Consistent with smad1/5 activation in response to GDF-2 treatment, I
observed clear nuclear translocation of smad1/5 [Figure 6.3] in 4T1 cells, a
mouse mammary epithelial model. Therefore, I concluded that GDF-2 exclusively
mediates smad1/5 phosphorylation and signaling.
6.2 GDF-2 induces phosphorylation of linker region of smad2 but not
smad1 and this might be via the MAPK pathway
It has been previously observed that BMPs induce smad1 linker
phosphorylation at four different MAPK phosphorylation sites (Ser-187, 195, 206
and 214) [52]. The MAPK mediated phosphorylation of the linker region generally
results in the inhibition of smad1 activity [43, 48] and attenuation of the nuclear
accumulation of smad1 [43]. Similarly, TGFβ induced MAPK mediated
attenuation of smad2 activity has been attributed to smad2 linker phosphorylation
[44, 49]. Therefore, to find out whether GDF-2 is also inducing smad1 linker
phosphorylation, I examined smad1 linker phosphorylation in different
tumorigenic cell lines [Figure 6.4].
Surprisingly, I observed that GDF-2 did not induce smad1 linker
phosphorylation, although it very clearly induces smad1/5 phosphorylation in
both tumorigenic and non-tumorigenic cell lines. Historically, it has been known
that GDF-2 is not able to induce smad2/3 phosphorylation and subsequently, it’s
signaling [10] and it has always been associated with smad1/5 signaling. But
since, I did not observe any smad1 linker phosphorylation in any of the cell lines,
I opted to see if GDF-2 could induce smad2 linker phosphorylation and
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surprisingly, I observed smad2 linker getting phosphorylated by GDF-2 in a time
dependent manner [Figure 6.5]. This observation is novel and there are no
previous reports of smad2 linker region getting phosphorylated by GDF-2.
Smad1 linker region gets phosphorylated by MAPKs [43, 48, 52] and although I
could not observe any smad1 linker phosphorylation by GDF-2, I could clearly
conclude that GDF-2 is phosphorylating the smad2 linker. .
To find out whether MAPK pathway is involved in this phenomenon, I took
the help of two inhibitors: U0126 (MEK inhibitor) and SB203580 (p38 MAPK
inhibitor). It was again surprising to observe that the two inhibitors, individually,
and in a combinatorial way, were able to suppress smad2 linker phosphorylation
mediated by GDF-2 [Figure 6.6].
Thus, I was able to make the conclusion that GDF-2 induces smad2 but
not smad1 linker phosphorylation in a subset of tumorigenic epithelial cells and it
might be mediating that via MAPK pathway.
6.3 GDF-2 mediates the retention of linker-phosphorylated smad2 in the
cytoplasm and it does not allow the nuclear translocation of C-terminal
phosphorylated smad2
Linker phosphorylation of smads in the basal state leads to their
cytoplasmic retention and ubiquitin ligase-driven; proteasomal degradation [51,
52], with a concomitant decrease in the responsiveness of cells to BMP and
TGFβ signals [43, 44, 48, 49]. Smad linker phosphorylation by antagonists
provides a critical counterbalance to TGFβ and BMP signaling. This has led to
postulates that in the canonical pathways, C-tail phosphorylation activates smad
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signaling and linker phosphorylation inhibits it [52, 53]. Also, TGFβ is historically
known to phosphorylate smad2/3 and mediate it’s signaling [64] and it also
promotes the nuclear translocation of smad2/3 for target gene regulation. To find
out whether GDF-2 exhibits the same effects as TGFβ in retaining smad2 in the
cytoplasm after it’s linker region gets phosphorylated, I did subcellular
fractionation in HEY cells and separated the cytosolic and nuclear fraction. Then
the different fractions were blotted for phosphorylated smad2 linker and
phosphorylated C-terminal of smad2 [Figure 6.7]. I observed that when the linker
region of smad2 gets phosphorylated, surprisingly almost all of smad2 gets
retained in the cytoplasm. Thus, it was clearly evident that GDF-2 acts in the
same manner as TGFβ while phosphorylating the linker region of smad2 and
then the retention of it in the cytoplasm. The interesting part of this observation is
that although GDF-2 falls under the TGFβ superfamily, it is not at all similar to
TGFβ and is expected to act in a manner similar to the other BMPs, since GDF-2
also induces smad1/5 phosphorylation.
Therefore, the reason why GDF-2 cannot induce smad2/3 C-terminal
phosphorylation and mediates it’s nuclear translocation might be due to the fact
that GDF-2 induces smad2 linker phosphorylation and hence, inhibits it’s
downstream canonical signaling.
6.4 GDF-2 might be inhibiting the TGFβ mediated smad2/3 signaling
pathway and it may be doing it via smad2 linker region phosphorylation.
The next step of my research was to find out the consequences of the
smad2 linker phosphorylation by GDF-2. There have been many previous reports
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of smad linker phosphorylation by TGFβ and BMPs, and all are related to the fact
that the linker phosphorylation of the smads helps them to get retained in the
cytoplasm and subsequently attenuates their nuclear accumulation, which in turn
inhibits BMP or TGFβ signaling [43, 44, 48, 49]. I assumed that there might be
some biological consequences of smad2 linker phosphorylation by GDF-2 due to
the known fact that linker phosphorylation disrupts nuclear translocation of smad
proteins. Since it was a novel observation that GDF-2 is able to phosphorylate
smad2 and not smad1 linker, I proceeded to study the effects of GDF-2 mediated
smad2 linker phosphorylation on TGFβ mediated signaling with the luciferase
reporter assay, as TGFβ is known to be the ligand which phosphorylates
smad2/3. HEY and SKOV3 cells were transfected with pE2.1-luciferase, a
luciferase reporter gene under the control of TGFβ responsive PAI-1 based
promoter and the GDF-2 mediated gene induction with and without TGFβ was
assayed by measuring luciferase activity [Figure 6.8].
As evident from the figure above that gene induction by TGFβ is
approximately 3- fold down in the presence of GDF-2 in HEY, and almost 1.5-fold
down in SKOV3. This might be due to the fact that GDF-2 is suppressing TGFβ
mediated signaling via smad2, by phosphorylating the linker region of smad2,
which subsequently are not being able to translocate into the nucleus, thus
lowering the target gene expression.

24

Figure 6.1 GDF-2 activates smad1/5 in tumorigenic and non-tumorigenic
epithelial cells. Western blotting of lysates from (a) BT 474, (b) SKOV3, (c)
HEY, (d) OvCa 429, (e) MCF10A, (f) HMvEC, treated with GDF-2 (10ng/ml) for
the indicated times (minutes) and immunoblotted for psmad1/5 and smad1.

Figure 6.2 GDF-2 does not activate smad2/3 in epithelial cells. Western
blotting of lysates from (a) OvCa 429, (b) HEY, treated with GDF-2 (10ng/ml) for
the indicated times (minutes) and immunoblotted for psmad2/3 and smad2.
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Figure 6.3 SMAD1 translocates into the nucleus. Immunofluorescence images
of 4T1 cells treated with GDF-2 for 30 minutes, followed by immunostaining for
smad1

Figure 6.4 GDF-2 does not induce smad1 linker phosphorylation in
tumorigenic epithelial cells. Western blotting of lysates from (a) SKOV3, (b)
HEY, (c) BT 474, treated with GDF-2 (10ng/ml) for the indicated times (minutes)
and immunoblotted for psmad1 linker and smad1.
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Figure 6.5 GDF-2 induces smad2 linker phosphorylation in tumorigenic
epithelial cells. Western blotting of lysates from (a) HEY, (b) SKOV3, (c) BT
474, treated with GDF-2 (10ng/ml) for the indicated times (minutes) and
immunoblotted for psmad2 linker and smad2.

Figure 6.6 GDF-2 might be inducing smad2 linker phosphorylation via
MAPK pathway. Western blotting for psmad2L activation in (a) HEY and (b)
SKOV3 in the presence and absence U0126 (10µM) and SB203580 (10µM) with
and without GDF-2 (10ng/ml) as indicated.
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Figure 6.7 GDF-2 mediated smad2 linker phosphorylation inhibits smad2 to
translocate into the nucleus. HEY cells were treated with GDF-2 (10ng/ml) and
fractionated into nuclear and cytoplasmic fractions. Twenty micrograms of protein
were loaded from each fraction for western blotting and immunoblotted for
psmad2 linker, psmad2/3 (C-terminal), smad2, GAPDH and fibrillarin. GAPDH
and fibrillarin is cytoplasmic and nuclear marker, respectively.
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Figure 6.8 GDF-2 is able to suppress TGFβ mediated signaling. (a) HEY and
(b) SKOV3 cells were transfected with pE2.1-luciferase and treated with GDF-2
(10ng/ml) and TGFβ (100pM). The cells were then assayed by measuring
luciferase activity. Data are shown as fold induction (relative to untreated cells).
Statistical analysis was carried out using the paired t-test, ★★ = P<0.0001.
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CHAPTER 7

DISCUSSION

My study shows for the first time a role of GDF-2 in inducing smad2 linker
phosphorylation in epithelial cells [Figure 6.5]. It has been historically observed
that BMPs and GDF-2 are able to induce smad signaling but it is somewhat
restricted to smad1/5 [Figure 6.1], and BMPs are also shown to induce smad1
linker phosphorylation but never smad2 or smad3 [1-5]. Therefore, my
assumption was that GDF-2 would also induce smad1 linker phosphorylation and
not smad2 linker. But I observed that GDF-2 is inducing smad2 linker
phosphorylation instead of smad1 linker, which has not been reported before. I
also noticed that GDF-2 is promoting the retention of smad2 in the cytoplasm via
the phosphorylation of smad2 linker not allowing for it’s nuclear translocation
[Figure 6.7]. The novelty in these observations is that GDF-2 is somehow
mimicing TGFβ and showing the same effects on smad linker phosphorylation. I
observed that similar to TGFβ’s induction of linker phosphorylation via MAPK
pathway [43, 44, 48, 49], GDF-2 is also able to activate the MAPK proteins and in
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turn induce the linker phosphorylation of smad2 [Figure 6.6]. Another aspect of
my study was to look for GDF-2’s ability to suppress TGFβ mediated signaling.
With the help of luciferase gene reporter assay, I was able to conclude that GDF2 is indeed suppressing TGFβ mediated signaling. There are a lot of areas where
this study can further go. The first of them would be to look for the different
receptors (type I, II or III), which are responsible for bringing about the
phosphorylation of linker region of smad2. One of the issues is that epithelial
cells have very low levels of ALK1, which is known to be the specific receptor for
GDF-2 in endothelial cells. Although previous studies have shown that GDF-2
can act via ALK2 [4, 15] or ALK3 (unpublished data from our group), and it’s
capacity to induce smad signaling is enhanced in the presence of Endoglin (a
type III receptor) [65, 66], the question remains as to whether these receptors are
also able to induce the linker phosphorylation in smads. There are different sites
of phosphorylation in smads where MAPK proteins can phosphorylate. It is not
known whether the same residues, which are getting phosphorylated by GDF-2,
are the ones, which are responsible for TGFβ’s suppression, by GDF-2. Site
directed mutagenesis might be one of the ways to study this particular effect of
GDF-2 on TGFβ. Linker phosohorylation of smads might be one of the key
aspects of smad dynamics between the cytoplasm and nucleus. It’s downstream
biological consequences and relevance like cell proliferation, migration, invasion,
might be used for therapeutical approaches.
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